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The COVID-19 epidemic has been a great challenge to health systems and especially
hospitals. A prospective observational epidemiological study was planned as of February
26, 2020 in a tertiary hospital in the Valencia region. The total number of patients followed
up with complete information during the first year was 2,448. Among other variables, the
comorbidities of the patients were collected (and grouped in the Charson index), the
stay in the intensive care unit (ICU), the co-infections, and the colonizations. Data on
nosocomial infections due to said virus were also collected. The median days from the
onset of symptoms to diagnosis were 4 + 4.6, while an additional 4.4 days had to pass
for the patients to be admitted to the ICU. The factors associated with a higher risk of
death were those with coinfection, especially with Candida auris [odds ratio (OR): 4.6],
a situation that also occurred in the ICU (OR: 3.18). Charlson Index comorbidity and C.
auris colonization were also very important both in general hospitalization and in the ICU.
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INTRODUCTION
Since the first known cases were described in Wuhan at the end of 2019 (1), the infectious disease
caused by SARS-CoV-2 and christened as COVID-19 by the World Health Organization (2) has
become an unprecedented pandemic. It has tested the limits of scientific and health system capacity
with regard to understanding SARS-CoV-2 transmission mechanisms, physiopathology, the body’s
humoral and cellular immune response, and clinical presentation; building diagnostic capacity;
determining the best pharmacological and non-pharmacological treatments; and developing truly
effective and comprehensive control strategies. Fortunately, new knowledge is gradually being
generating in response to the unrelenting need imposed by the circumstances.
COVID-19 encompasses a wide clinical spectrum, as it can present as anything from an
asymptomatic or mild infection to severe pneumonia and respiratory failure, with the potential
to develop into a multiorgan syndrome. Its complications can even lead to death, with rapid onset
of acute respiratory distress syndrome in some patients (3).
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Prior to the pandemic, antimicrobial resistance in bacteria
and fungi was among the main health threats globally (4–6).
The impact of antibacterial and antimycotic resistance can
be minimized through adherence to recommendations on
the administration of antimicrobials and the implementation
of infection control measures. These practices are based on
the active detection of colonization with resistant pathogens
as well as compliance with strict precautions regarding the
isolation of carriers to prevent horizontal transmission among
patients (7, 8). Optimizing prescriptions of antimicrobials can be
challenging in patients with COVID-19, as the clinical severity,
imaging characteristics, and laboratory parameters complicate
the differentiation between bacterial coinfection and the effects of
SARS-CoV-2 itself. It is important to characterize the underlying
risk present in the patient’s situation; tools like the Charlson
comorbidity index can be useful in defining diverse clinical
conditions predictive of mortality (9) and that can influence
prognosis and confer added risk.
Finally, as part of the treatment strategy and considering the
above, it is necessary to adapt infection control programs and
administration of antimicrobial agents in real time to evolving
and updated scientific evidence (7). The aim of this study is
to determine the importance that infection and/or colonization
with multidrug-resistant germs has on outcomes in COVID-19,
taking into account patient comorbidities.
MATERIALS AND METHODS
Data and Analysis
The study was carried out in a tertiary hospital in Valencia, Spain.
This Hospital has a Preventive Medicine Service that is dedicated
to the control of hospital isolations and infections. It also has an
accredited Microbiology Service in its procedures and cultures.
This was an observational epidemiological study with
prospective follow-up; it was still ongoing at the time of
writing. Patients were enrolled upon admission to hospital
for COVID-19, starting on 27 February 2020; we report on
outcomes to 26 February 2021, that is, at one natural year from
study commencement.
Data were collected on a daily basis from our own electronic
healthcare databases, with continuous cross-referencing, for all
COVID-19 patients admitted to a public tertiary hospital in the
province of Valencia (Spain) (N = 2,448). The hospital is the
reference center for microbiological testing for a large part of the
province of Valencia (more than 500,000 inhabitants), especially
Health Department number 9.
The study included all patients admitted for more than
24 h; identifying information was anonymized in accordance
with regulations on patient confidentiality and personal data
protection laws.
Variables analyzed were: age, sex, mean length of hospital
stay for COVID-19 (days), mean length of stay in patients
admitted to the intensive care unit (ICU), date of symptoms
onset, date of discharge for COVID-19, type of coinfection,
and/or colonization, classified as: Candida auris, multidrug-
resistant germs, or both; Charlson index (scoring according to
that index), time from symptoms onset to hospital admission
(days), and type of discharge (death, yes/no). In this study co-
infection is when two or more germs are in or on the body and
make you sick, which results in signs and symptoms such as fever,
pus from a wound, a high white blood cell count, diarrhea, or
pneumonia. Colonization means germs are on the body but do
not make you sick. People who are colonized will have no signs
or symptoms (10).
The Charlson index included 19 comorbidities for which
points were assigned to patients, in line with the classification (9).
The group of multidrug-resistant germs comprised all the germs
classified as such in the hospital antibiogram.
Some variables were recoded: age was transformed into a
categorical variable by 10-year age groups in the descriptive
analysis and length of hospital stay (ward/ICU) was categorized
in intervals of 10 days. Charlson index scores were considered
both as an ordinal variable (1, 2, 3,...6), with all scores of 7 ormore
grouped into a single category, and as a dichotomous variable (0
points vs. ≥1 point).
The length of hospital stay was considered only for the
time admitted to the corresponding unit, until the patient
was considered “COVID-19-free” or was discharged to their
residence, nursing home, or even another hospital ward when an
additional pathology required it.
Statistical Analysis
Quantitative variables are described as means (standard
deviation, SD), but for the distribution from symptoms onset
to hospital admission including nosocomial transmission we
used median and SD. The normality of the distribution was
tested using the Kolmogorov-Smirnov statistic, and means were
compared first with Levene’s test of equal variances and then with
the student’s t-test. Variables were grouped, covariances studied,
and simple and multiple logistic regressions performed, with
analysis of possible interactions and confounding. For small,
non-parametric samples, we used the Mann-Whitney U- and
Wilcoxon W-tests.
Independence and multicollinearity of the variables were
assessed using the Durbin Watson and variance inflation
factor tests. Goodness-of-fit was also assess using the
Hosmer-Lemeshow test. We calculated odds ratios (ORs)
with their 95% confidence intervals (CIs) for all variables,
including dummy variables. P-values of <0.05 were considered
statistically significant.
Analyses were undertaken with SPSS software for Windows
(version 26.0, IBM Corp., Armonk, NY).
Study Setting and Population
A specific COVID-19 unit with established treatment protocols
was created to attend patients.
To assess antibiotic resistance, gram-positive germs were
tested with betalactams, aminoglucosides, and other antibiotics
like vancomycin, levofloxacin, and linezolid. Gram-negative
germs were exposed to betalactams, piperacillin/tazobactam,
imipenem, aminoglucosides, and others such as ciprofloxacin
and fosfomycin. Resistance to meropenem (minimum inhibitory
concentration ≥8 mg/L) was considered indicative of resistance
to all carbapenems (11).
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Gender Men 1,345 54.9 54.9
Women 1,103 45.1 100
Age group (years) 0–10 15 0.6 0.6
11–20 8 0.3 0.9
21–30 51 2.1 3.0
31–40 145 5.9 8.9
41–50 277 11.3 20.3
51–60 384 15.7 35.9
61–70 407 16.6 52.6
71–80 514 21.0 73.6
81–90 480 19.6 93.2
91–100 164 6.7 99.9
>100 3 0.1 100
Month of admission Feb-20 3 0.1 0.1
Mar-20 227 9.3 9.4
Apr-20 119 4.9 14.3
May-20 17 0.7 15.0
Jun-20 8 0.3 15.3
Jul-20 7 0.3 15.6
Aug-20 105 4.3 19.9
Sep-20 87 3.6 23.4
Oct-20 168 6.9 30.3
Nov-20 327 13.4 43.6
Dec-20 391 16.0 59.6
Jan-21 727 29.7 89.3
Feb-21 262 10.7 100
Length of hospital stay
(including ICU stay), in
days
0–10 1,542 63.0 63.0
11–20 622 25.4 88.4
21–30 176 7.2 95.6
31–40 42 1.7 97.3
41–50 31 1.3 98.6
51–60 16 0.7 99.2
61–70 5 0.2 99.4
71–80 7 0.3 99.7
81–90 1 0 99.8
91–100 1 0 99.8
>100 5 0.2 100





Diabetes 309 20 51






Rheumatologic disease 139 9 83,04
Other comorbidities 262 16,96 100
Coinfection with MDR Non 2,079 84.93 84.93
Yes 369 15.07 100,00
(Continued)
TABLE 1 | Continued
N % Cumulative
%
Type of MDR Escherichia coli 101 27.37 27.37








Others 27 7.32 100,00
Type of discharge No death 1,974 80.6
Death 474 100
MDR, multidrug resistance.
For C. auris, susceptibility was interpreted according to the
cutoffs proposed by the US Centers for Disease Control and
Prevention (12). All strains of C. auris considered in the present
study demonstrated resistance to amphotericin B and had shown
greater susceptibility to azoles and echinocandins. In addition
to collecting test swabs, microbiological samples were taken
in case of clinical suspicion of infection. The microorganisms
cultured from the blood samples, nasopharyngeal specimens,
or urine were identified by means of MALDI-TOF mass
spectrometry, antimicrobial susceptibility tests were performed
with the Vitek2 system (Biomerieux, Craponne, France), and
antifungal testing employed the microdilution method of the
Clinical and Laboratory Standards Institute and the Sensititre
YeastOne panel (Thermo Scientific, Waltham, MA, USA).
Bacterial infection was defined as an acute infection that
included both the coinfection at the time of presentation and the
secondary infection that emerged over the course of the illness
and the hospital stay, as we could not always distinguish between
these. We considered colonization based on the same criteria.
Microbiological eradication was defined by negative cultures
during follow-up plus improvement in clinical and laboratory
parameters. Clinical cure was defined as clinical improvement
without evidence of microbiological eradication.
The primary outcome was colonization or the development
of infection with multidrug-resistant germs, C. auris, or both in
inpatients with COVID-19.
This study protocol was conducted according to the guidelines
of the Declaration of Helsinki and approved by the Valencia
University General Hospital Ethics Committee. The information
obtained was treated with absolute confidentiality, respecting
the principles of the Declaration of Helsinki. Participants’ data
were anonymized upon extraction. All patients, when invited
to be included in the health system through their personalized
identification number, gave their authorization to the Regional
Ministry of Health for their information to be used for research
purposes, in compliance with data protection regulations.
RESULTS
A total of 2,448 patients were admitted and discharged over
the study period, including 364 people admitted to the ICU.
Table 1 presents patients’ baseline characteristics. Approximately
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TABLE 2 | Days from symptoms onset to hospital admission, including in
nosocomial cases.
Days N % Cumulative %
Nosocomial 28 1.1 1.1
0 258 10.5 11.7
1 375 15.3 27.0
2 262 10.7 37.7
3 172 7.0 44.7
4 170 6.9 51.7
5 164 6.7 58.4
6 158 6.5 64.8
7 235 9.6 74.4
8 162 6.6 81.0
9 114 4.7 85.7
≥10 350 14.3 100
Total 2,448 100.0
55% were men, and the mean age was 66.7 years (SD 18.3). On
average, women were older than men (68.9 vs. 64.8 years, p >
0.05). The age group with the most representation was 71–80
years, comprising 21% of the sample. Admission trends showed
clear waves of COVID-19 infections. The first, starting in March
2020, showed the largest month-to-month increase in admissions
in the entire study period. Admissions fell to very low levels
until August 2020, when cases again started to increase at rates
of 1,000%. Admissions increased at low rates, especially at the
beginning of December 2020, until a third wave of infections
started, resulting in an increased rate of admissions (85%) in
January 2021, before starting to fall again in February 2021.
Mean length of hospital stay in the total sample was 11.6 days
(SD 11.5), while for ICU patients it was 13.9 days (SD 14.5).
Notably, 36.9% of the patients had a Charlson comorbidity score
of 0. It should be underlined that in patients with comorbidity,
COPD, and diabetes were themost frequent pathologies, together
accounting for slightly more than 50%. On the other hand, 15%
of the patients admitted for COVID-19 had a co-infection with
MR germs, the most frequent germs being Escherichia coli and
Klebsiella pneumoniae, which together accounted for 50% of all
co-infections. In addition to the above, it is worth noting that the
overall mortality rate for all inpatients, including ICU patients,
was 19.4%.
Table 2 presents data on the interval from symptoms onset to
hospital admission, as reported by patients, as well as the date of
admission. Although the data set was widely dispersed, the three
groups with the shortest interval (0, 1, and 2 days from onset
to admission) made up over 36% of the total. There was also a
relatively large proportion (14.3%) who had had symptoms for
over 10 days before presenting to the emergency department and
being admitted.
Regarding the median days from symptoms onset to
diagnosis, and not counting patients with nosocomial infections,
this interval was 4 (SD 4.6) days. Patients acquiring COVID-19
by nosocomial transmission had been admitted for a median 8.5
TABLE 3 | Characteristics of patients admitted to the ICU for COVID-19, February
2020 to February 2021.
N % Cumulative %
Gender Men 247 67.9 67.9
Women 117 32.1 100.0
Coinfection No coinfection 289 79.4 79.4
Candida auris alone 14 3.8 83.2
MDR germs alone 46 12.6 95.9
Both 15 4.1 100.0
Colonization No colonization 252 69.2 73.9
Candida auris alone 29 8.0 80.5
MDR germs alone 59 16.2 93.1
Both 24 6.6 100.0
Charlson
comorbidity
0 95 26.1 26.1
1 104 28.6 54.7
2 80 22.0 76.7
3 32 8.8 85.5
4 23 6.3 91.8
5 5 1.4 93.1
6 15 4.1 97.3
≥7 10 2.7 100.0
Length of ICU stay,
days
0–10 211 58.0 58.0
11–20 73 20.1 78.1
21–30 21 5.8 83.9
31–40 19 5.2 89.1
41–50 16 4.4 93.5
51–60 3 0.8 94.3
61–70 2 0.5 94.8
71–80 1 0.3 95.1
>81 18 4.9 100.0
Type of discharge No exitus 251 69.0 69.0
Exitus 113 31.0 100.0
MDR, multidrug-resistant; Both, MDR and Candida auris.
(7.2) days, with no differences between the 21 men and 7 women
in this group.
Among the 364 patients admitted to the ICU (Table 3), there
was a preponderance of men (68%). Mean age was 63.7 (SD
13) years, with no difference according to gender (student’s
t-test p > 0.05). About 20% of the ICU patients presented
coinfections (in addition to COVID-19), being almost 6%
higher than co-infections found in other hospitalized patients.
Multidrug-resistant germs were behind approximately 13% of the
infections, and C. auris was responsible for 4%. The percentage
of patients with colonization was higher, reaching 30.8%, while
the mortality rate was 31.04%. The median interval between
symptoms onset and ICU admission was 8.4 (SD 7.7) days,
and it is worth noting the fact that 60% of the patients
admitted to the ICU did not exceed a stay of 10 days in
the ICU.
Table 4 presents the results of the analysis of variables
associated with mortality among COVID-19 patients admitted
to the ICU. The strongest association observed was for Charlson
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TABLE 4 | Multivariable logistic regression for mortality in patients admitted to the ICU with COVID.
β SE Wald df P-value OR 95% CI
Days from symptoms onset to admission −0.04 0.03 2.39 1 0.12 0.96 0.91 1.01
Male sex −0.12 0.31 0.15 1 0.70 0.89 0.48 1.64
Age (years) 0.001 0.01 0.01 1 0.92 1.00 0.98 1.03
Charlson (points) 14.65 7 0.04
Charlson (1) 0.98 0.56 3.08 1 0.079 2.67 0.89 7.98
Charlson (2) 1.49 0.58 6.47 1 0.011 4.42 1.41 13.88
Charlson (3) 0.63 0.74 0.73 1 0.39 1.88 0.44 8.02
Charlson (4) 1.41 0.74 3.68 1 0.055 4.09 0.97 17.26
Charlson (5) 1.75 0.90 3.80 1 0.051 5.73 0.99 33.08
Charlson (6) 1.80 0.69 6.78 1 0.009 6.06 1.56 23.48
Charlson (≥7) 2.10 0.66 10.24 1 0.001 8.14 2.25 29.42
Infection 13.48 3 0.004
C. auris alone 1.16 0.62 3.51 1 0.061 3.18 0.95 10.65
MDR germs alone 1.26 0.39 10.35 1 0.001 3.52 1.64 7.58
C. auris + MDR germs 1.12 0.52 4.65 1 0.031 3.07 1.11 8.52
Colonization 2.04 3 0.57
C. auris alone 0.76 0.56 1.83 1 0.18 2.13 0.71 6.37
MDR germs alone 0.30 0.40 0.56 1 0.45 1.35 0.61 2.99
C. auris + MDR germs 0.13 0.58 0.05 1 0.82 1.14 0.37 3.56
Length of ICU stay (days) 0.01 0.02 0.84 1 0.36 1.01 0.98 1.05
Constant −3.35 0.96 12.12 1 < 0.001 0.04
CI, confidence interval; df, degrees of freedom; MDR, multidrug-resistant; OR, odds ratio; SE, standard error.
comorbidity, especially for scores of 7 or more (OR 8.14 95%
CI 2.25, 29.42), followed by Charlson scores of 6 or more (OR
6.05, 95% CI 1.56, 23.48), infection with multidrug-resistant
germs (OR 3.52, 95% CI 1.64, 7.58), and coinfection with
both multidrug-resistant germs and C. auris (OR 3.07, 95% CI
1.11, 8.52).
Regarding the factors associated with a higher risk of death in
the total sample (Table 5), the most important was coinfection,
especially with C. auris (OR 4.64, 95% CI 3.12, 6.91) but
also with multidrug-resistant germs. And interestingly, here the
colonisations by Candida auriswere significant (OR: 2.36 95% CI
1.58. 3.52), as well as by MR germs and by the association of both
(OR: 1.65 95% CI 1.65, 2.35). Charlson indexes of 6 points and 7
or more points were also linked to higher mortality. Notably, age
had virtually no statistically significant influence when the effect
of comorbidity, gender, co-infections, and average hospital stay
were removed.
DISCUSSION
To our knowledge, this is one of the few prospective studies with
up to 1 year of follow-up assessing the influence of multidrug-
resistant pathogens on mortality in patients hospitalized for
COVID-19. The pandemic has interrupted life in general and
hospital routines in particular, with many centers compelled to
provide diagnostic and treatment services exclusively to those
with suspected or confirmed COVID-19. This narrow focus
has been applied without sufficient consideration for other
possible factors, including colonization and infection. There are
many published studies and even meta-analysis on predictors
of mortality (13), but the vast majority are small in size and
practically none include colonizations of germs that are so
important today.
The crude mortality rate in our study population of inpatients
during the first year of the pandemic was 19.4%, within the range
of other studies reporting rates of 4–28%, although generally
other studies have had smaller populations (14), especially with
regard to those admitted to the ICU (15, 16). In our study, the
median interval from onset to admission, not counting those with
nosocomial infections, was slightly shorter at 4.6 days than the 7-
day interval reported in a retrospective multicenter cohort study
from the Netherlands (17), which may reflect a faster and more
severe evolution in our patients. Unlike other studies (18), we
did not find a higher risk in men after adjusting for comorbidity
and age.
Compared to the literature, the mean length of hospital
stay was relatively high at 11.6 days. A US study based
on administrative data observed a mean stay of just 7 days
(in a selected population of adults) (19), similar to another
retrospective study using an administrative database in Australia
(20), and another in a small sample of patients precisely in
Wuhan but in only 1 month of 2020 (21).
According to theWHO, there is currently an alarmingly rapid
propagation of multidrug-resistant and pan-resistant bacterias
(also known as “superbacterias”), causing infections that cannot
be treated with existing antimicrobials (22). While antibiotics are
not effective for COVID-19, they are nevertheless administered
to patients with suspected or confirmed COVID-19 infections,
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TABLE 5 | Multivariable logistic regression for mortality in total sample of patients admitted to hospital for COVID-19.
β SE Wald df P-value OR 95% CI
Days from symptoms onset to admission 0.003 0.011 0.091 1 0.76 1.00 0.98 1.02
Male sex 0.009 0.11 0.006 1 0.94 1.01 0.82 1.25
Age (years) −0.006 0.003 4.11 1 0.04 0.99 0.99 1
Charlson (points) 15.86 7 0.026
Charlson (1) 0.26 0.15 3.10 1 0.078 1.29 0.97 1.72
Charlson (2) 0.32 0.16 3.90 1 0.048 1.38 1.00 1.91
Charlson (3) 0.18 0.20 0.81 1 0.37 1.20 0.81 1.79
Charlson (4) 0.039 0.20 0.039 1 0.84 1.04 0.71 1.52
Charlson (5) −0.081 0.42 0.038 1 0.85 0.92 0.41 2.09
Charlson (6) 0.88 0.29 9.17 1 0.002 2.42 1.37 4.28
Charlson (≥7) 0.81 0.36 5.11 1 0.024 2.25 1.11 4.53
Infection 70.29 3 0
C. auris alone 1.54 0.20 57.33 1 0 4.64 3.12 6.91
MDR germs alone 0.75 0.16 22.27 1 0 2.11 1.55 2.88
C. auris + MDR germs 0.086 0.25 0.12 1 0.73 1.09 0.66 1.79
Colonization 25.50 3 0
C. auris alone 0.86 0.20 17.70 1 0 2.36 1.58 3.52
MDR germs alone 0.40 0.15 6.83 1 0.009 1.49 1.10 2.00
C. auris + MDR germs 0.50 0.18 7.84 1 0.005 1.65 1.16 2.35
Length of hospital stay (days) 0.01 0.027 0.105 1 0.74 1.01 0.95 1.06
Constant −2.05 0.25 67.96 1 0 0.13
CI, confidence interval; df, degrees of freedom; MDR, multidrug-resistant; OR, odds ratio; SE, standard error.
for several reasons. For one, it is difficult to rule out a bacterial
coinfection at the time of presentation, and moreover, there is a
risk of a secondary bacterial infection during the course of the
disease. Because researchers have extrapolated information on
the increased mortality in patients with bacterial superinfection
during flu pandemics, empirical antibiotics are used for patients
with severe COVID-19 (23). In our study, just 21% of our
COVID-19 patients had a coinfection, and this was associated
with an added risk for the patient. On the other hand, a
much larger proportion—63%—had a Charlson index of 1 point
or more.
Azithromycin is probably one of the most commonly
administered treatments for inpatients with COVID-19, both
in general (24–26) and in our center. This antibiotic belongs
to the family of macrolides, which is used against a wide
range of bacterial diseases; however, it has also been shown
to have antiviral and immunomodulating properties that could
be of interest in viral infections like COVID-19. Its value for
preventing coinfections is unknown.
Co-infections continue to be important in COVID-19
mortality, as has been progressively established (15, 16).
However, in this study, mortality was also associated with
colonization by both MR and C. auris germs or both
simultaneously, a situation that has not been reported in
published studies so far. It may be that the germ in the carrier
state is able to enter the human body when it finds a route
of access or a significant decrease in immunity and ends up
producing a co-infection as has been described in other infectious
conditions (8).
One reflection of the greater severity and difficulty for treating
COVID-19 is the fact that the mean length of hospital stay was
longer than the overall average (7.2 days) for all inpatients in the
year prior to the pandemic. The additional 4.5 days they spent in
hospital could increase the risk of infections. Something similar
occurred in the patients admitted to the ICU, indicating greater
clinical complexity and a subsequently higher risk of coinfections
and colonization, an added risk for nosocomial infections.
It is known that the outbreaks of C. auris that occur in
patients with COVID admitted to the ICU are very important
and their containment is very difficult, as is widely documented
(27, 28). Due to the nature of hospital care in COVID-19, health
professionals often wear the same personal protective equipment
to attend different patients. This practice may have increased
the risk of horizontal transmission, even though these patients
have always been indicated for isolation protocols. However,
in our case we cannot document the horizontal transmission
due to difficulties cloning C. auris and/or multidrug-resistant
germ chains.
The consequences of colonization/infection by multidrug-
resistant bacteria have not yet been evaluated in patients
with COVID-19, but they could be concerning for several
reasons. First of all, these patients already experience immune
system dysfunctions, both because of the disease itself and
the immunomodulating therapies administered to treat it.
Secondly, hospital COVID-19 cases have a profile characterized
by advanced age, comorbidities, prolonged hospital stays, and
numerous invasive procedures, all of which are risk factors for
colonization or infection by multidrug-resistant bacteria.
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There seems to be evidence that some serological markers of
inflammation associated with bacterial infections, like elevated
procalcitonin and C-reactive protein, can appear in patients with
COVID-19 (29) without any bacterial coinfection. However, in
our study we used only the germ cultures and their corresponding
resistance, so this limitation does not apply.
Another important variable we assessed was comorbidity,
adjusted for age, sex, and infection/colonization. Comorbidity
has been studied in an ad hoc way conjunction with age in
patients with COVID-19 (13, 30–32), but in this patient group, it
is more appropriate to use standardized comorbidity indicators
that are quantitatively associated with mortality, such as the
Charlson comorbidity index. One study of COVID-19 did use
that indicator; however, the sample was limited to people aged
40–85 years (33), unlike ours; moreover, when age was adjusted
for comorbidity, it did not influence mortality.
Many of the components of the Charlson index have been
individually linked to higher mortality in COVID-19, including
diabetes (13, 34) and chronic obstructive pulmonary disease
(35), among others, as cardiovascular diseases (36). Thus, it is
unsurprising that this tool is useful for measuring composite
mortality risk in this population, even after adjusting for
other factors.
Among the main limitations of this study, we included
patients with nosocomial infections. However, we considered
that these cases generally originate in routine hospital activities,
and these are often the patients with the poorest outcomes.
Our sample was also quite heterogeneous, and it was sometimes
difficult to obtain data for patients were referred from private
hospitals. It is even possible that these referrals led to an increase
in coinfections and colonization in some patients who were
carrying these infections upon admission to our center.
In most cases, patients were not assessed for colonization on
the same day of admission, so it is not possible to conclude
whether all cases of colonization were acquired in hospital.
Moreover, detecting coinfections and colonization often depends
on clinical suspicion or investigation, as the symptoms may be
masked by those caused by COVID-19 itself. For the same reason,
patients did not always distinguish the onset of symptoms,
confusing them with the symptoms of respiratory pathologies or
others. When they presented to the emergency department, they
often did not suspect that they had COVID-19 and had delayed
seeking care until their condition had deteriorated substantially.
The implications of our results include the need to perform
more controls in patients with COVID-19 monitoring not
only infections, but also colonizations, all aimed at optimizing
isolation measures. In that respect, control of MR germs
(including Candida auris) is essential. Moreover, there is a clear
need to characterize the difference in outcome with colonization
vs. infection with MDR.
Obviously, it is also necessary to continue assessing the
precise impact of COVID-19 in relation to the administration
of antimicrobials, infection control, and development of
appropriate public health strategies to prevent the propagation
of antimicrobial-resistant pathogens.
All in all, much remains to be studied, but the practical
importance that can be generated for the benefit of the patient
makes it worth the effort.
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